The Use of Bispectral Index Monitoring to Assess Depth of Sedation in Patients With Traumatic Brain Injury (BIS-TBI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Patients admitted to Aberdeen ICU with severe traumatic brain injury will have a BIS electrode placed and observed for 24 hours. The study team will be blinded to the result, so not to influence treatment.
All clinical care is at the discretion of the clinical team.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Aberdeen, United Kingdom, AB25 2ZN
- Intensive Care Unit, Aberdeen Royal Infirmary
-
Dundee, United Kingdom
- NHS Tayside
-
Edinburgh, United Kingdom
- NHS Lothian
-
Leeds, United Kingdom
- Leeds Teaching Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults (over 18)
- Diagnosis of traumatic brain injury
- Expected to survive
- Expected to require greater than 24 hours of sedation and mechanical ventilation
Exclusion Criteria:
- Brain injury thought to be unsurvivable by ICU clinical team
- Frontal decompressive craniectomy
- Use of ketamine infusion at recruitment or planned use within 24 hours
- Fractured frontal bone or severe overlying soft tissue injury
- Simple extradural haemorrhage with no other obvious intracranial injury
- Pregnant patient
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with TBI
Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
|
Unilateral BIS electrode
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean BIS for Population Over 24 Hours
Time Frame: 24 hours
|
Mean BIS of patients sedated.
BIS is a processed EEG value ranging from 0 to 100, with lower values representing decreased brain activity.
The usual range for General Anaesthesia is 40-60.
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean ICP for Population Over 24 Hours
Time Frame: 24 hours
|
Mean ICP of sedated patients
|
24 hours
|
|
Incidence of Osmotherapy Use for Population Over 24 Hours
Time Frame: 24 hours
|
Number of instances of osmotherapy use in sedated patients
|
24 hours
|
|
Median Vasopressor Dose for Population Over 24 Hours
Time Frame: 24 hours
|
Total vasopressor dose for sedated patients
|
24 hours
|
|
Sedative Dose for Population Over 24 Hours
Time Frame: 24 hours
|
Total sedative dose for sedated patients
|
24 hours
|
|
Length of ICU Stay for Population Over 24 Hours
Time Frame: Days to weeks
|
Number of days admitted to ICU
|
Days to weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Callum NA Kaye, MBChB, study principal investigator
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1-063-18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.